Tyra Biosciences
NASDAQ · TYRA·Carlsbad, CA·Small-cap·Phase 3
Clinical-stage precision oncology company developing FGFR inhibitors. Lead asset TYRA-300 is in Phase 3 SURF302 for muscle-invasive bladder cancer and Phase 2 for achondroplasia.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Tyra Biosciences Investor Presentation | Corporate overview | April 15, 2026 | 66 |